Studies reveal the promise of newly engineered bispecific antibodies against tumor cells news-medical.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news-medical.net Daily Mail and Mail on Sunday newspapers.
Antibodies Deplete Cancer Cells in Mice and Human Cell Lines by Angela Mohan on March 2, 2021 at 12:14 PM
Science,
Science Immunology.
Some immunotherapy approaches against cancers rely on common cancer-related mutations to serve as antigens; they instigate an immune response to the cancer.
Although it is one of the most common mutant tumor suppressor genes known in human cancers, the cancer-related p53 tumor suppressor gene has not been successfully targeted via this approach.
In
Science, Emily Han-Chung Hsiue and colleagues successfully engineered a bispecific antibody to reactivate p53. Hsiue et al. first identified a distinct targetable fragment of the mutant tumor suppressor protein and characterized the structural basis for how the fragment is presented to T cells.
Two of the three research studies led by Jacqueline Douglass, M.D., Ph.D. candidate at the Johns Hopkins University School of Medicine and Emily Han-Chung Hsiue, M.D., Ph.D., postdoctoral fellow at Johns Hopkins report on a precision medicine immunotherapy approach that specifically kills cancer cells by targeting mutant protein fragments presented as antigens on the cancer cell surface.
Although common across cancer types, p53 mutations have not been successfully targeted with drugs. Genetic alterations in tumor suppressor genes often resulted in their functional inactivation. Traditional drugs are aimed at inhibiting proteins. Inhibiting an already inactivated tumor suppressor gene protein in cancer cells, therefore, is not a feasible approach, says Hsiue, lead author on the
Three studies - one each in Science, Science Translational Medicine, and Science Immunology - reveal the promise of newly engineered bispecific antibodies, including by demonstrating their power against previously inaccessible tumor cell targets for the first time, in two cases.
Paul French Tuesday, 2 Mar 2021 – 7pm-8pm – Webtalk –
The event is free of charge for members. For guests or non members, the registration fee is $50. Please click here .
In this talk, well-known Chinese historian, raconteur and author Paul French talks of the Chinese capital telling numerous true stories of fascinating people who visited the city in the first half of the 20th century.
From Bolsheviks and Nazis, to artists and bank robbers, to English aesthetes, to transplanted New York Bowery Balladeers, he describes that extraordinary era. He asks the major question behind so many of these sojourners’ decisions to remain in the ancient capital – why Peking?